-
Analyst Coverage
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Enzon Pharmaceuticals Inc.s financial performance into perspective.
Analyst Coverage
Robert Hazlett
Bank of Montreal
James Molloy
Caris & Company
Ian Sanderson
Cowen and Company
Caroline V. Corner, PhD
WM Smith & Co.
Enzon Pharmaceuticals Inc. is currently followed by the brokerage firms listed above; this list may not be complete and is subject to change as firms add or delete coverage of Enzon. Please note that any opinions, estimates or forecasts regarding Enzon's historical or predicted performance made by the analysts at these firms are theirs alone and do not represent opinions, forecasts or predictions of Enzon, Inc or its management. Enzon is providing this listing as a service to its stockholders, and does not by listing these firms imply its endorsement of or concurrence with such information, conclusions or recommendations. Interested persons must obtain copies of analysts' reports on their own; Enzon does not distribute these reports. Various of these firms may be market-makers in Enzon stock and/or hold other long or short positions in the stock, and may provide compensated services to Enzon.
| (ENZN) NASDAQ | |
| Last Trade | 9.850 |
| Change(%) |
0.04
|
| Volume | 651,900 |
| Mar 9, 2010 3:59 PM ET | |
Sign up to receive Enzon Pharmaceuticals Inc. financial information by email.
News
-
Details on upcoming events are not yet available.
click here to be notified of all upcoming events.
-
02-17-2010
Fourth Quarter Earnings Call
-
11-03-2009
Third Quarter Earnings Call
-
08-05-2009
2009 BMO Capital Markets 9th Annual Focus on Healthcare Conference
-
08-04-2009
Second Quarter Earnings Call
-
Really Simple Syndication is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates.
-
03-08-2010
Enzon's Debt is Reduced by $116 Million
--Debt converted into an additional 13.5 million shares--
-
02-24-2010
Enzon Opens Pediatric Study of PEG-SN38
-
02-22-2010
Enzon Board of Directors Appoints Executive Committee
Jeffrey Buchalter Steps Down as CEO of Enzon
-
02-17-2010
Enzon Reports 2009 Results
--Sale of Specialty Pharmaceutical Business brings over $300 million in value--